

In re: Vyair Medical, Inc., et al.

Case No.: 24-11217 (BLS)
Reporting Period October 1 - 31, 2024

Supplementary Exhibit & Answers

Part 7, Question a. (Were any payments made on prepetition debt?):

The Debtors obtained post-petition financing consistent with the Interim Order Approving Motion to Approve Debtor In Possession Financing [Docket No. 103] and the Final Order (I) Authorizing the Debtors to Obtain Postpetition Financing, (II) Authorizing the Debtors to Use Cash Collateral, (III) Granting Liens and Providing Superpriority Administrative Expense Claims, (IV) Granting Adequate Protection, (V) Modifying Automatic Stay, and (VI) Granting Related Relief [Docket No. 248].

Part 7, Question c. (Were any payments made to or on behalf of insiders?):

Payments made on behalf of insiders include only regular salary and compensation to the Debtors' CEO, CFO, General Counsel, and/or independent directors.

Part 7, Question g. (Was there any postpetition borrowing, other than trade credit?):

The Debtors obtained post-petition financing consistent with the *Interim Order Approving Motion to Approve Debtor In Possession Financing* [Docket No. 103].

In re: Vyair Medical, Inc., et al.

24-11217 (BLS)

Statement of Cash Receipts and Disbursements

October 1 - 31, 2024

	Vyair Medical, Inc. (Consolidated)
Operating Receipts	
Collections	\$ 7,518,835
Total Operating Receipts	7,518,835
Operating Disbursements	
Trade Vendors	(7,171,860)
Payroll & Comissions	(5,608,683)
T&E Credit card	(561,474)
State and other taxes	(227,840)
Insurance	(89,262)
Customs Duty	(761)
Inter-company transfers	1,037,778
Total Operating Disbursements	(12,622,102)
Net Cash Flow from Operations	(5,103,267)
Non- Operating Receipts / (Disbursements)	
Other Non-Estate Receipts	1,322,374
Other Non-Operational	46,166,774
Total Non- Operating Receipts / (Disbursements)	47,489,148
Total Net Cash Flow	42,385,881
Restructuring Receipts/(Disbursements)	
DIP Draw	(13,750,000)
Professional Fees	(15,974,897)
D&O, Critical Vendor, and Other Contingency	(133,750)
Total Restructuring Receipts/(Disbursements)	(29,858,647)
Liquidity	
Book Cash Balance - Start	2,222,871
Net Cash Flow (+/-)	12,527,234
Change in Outstanding ACH/Wire/Check Balance	(136,083)
Book Cash Balance - End	14,614,023

In re: Vyaire Medical, Inc., et al.
24-11217 (BLS)
Balance Sheet
October 31, 2024

[illegible]

In re: Vyair Medical, Inc., et al.
24-11217 (BLS)
Income Statement
October 1 - 31, 2024

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28
	Vyaire Medical, Inc.	Bird Products Corporation	Breathes US HoldCo, Inc.	Breathes US Holdings LP	EME Medical, Inc.	Revolutionary Medical Devices, Inc.	SensorMedics Corporation	VIASYS Holdings Inc.	VM Finance Sub, LLC	Vyaire Company	Vyaire Finance B.V.	Vyaire Financial Holdings LLC	Vyaire Holding Company	Vyaire Medical 202, Inc.	Vyaire Medical 203, Inc.	Vyaire Medical 205, Inc.	Vyaire Medical 206, Inc.	Vyaire Medical 211, Inc.	Vyaire Medical BR LLC	Vyaire Medical Capital LLC	Vyaire Medical Consumables LLC	Vyaire Medical International LLC	Vyaire Medical LLC	Vyaire Medical Payroll LLC	Vyaire Receivables LLC	Vyaire Respiratory Diagnostics LLC	Vyaire TSR MidCo, LLC	Vyaire TSR Sub, LLC
Revenue																												
Third Party Revenue	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 1,445,086	\$ -	\$ -	\$ 665,034	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Intercompany Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	145,744	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,590,830	-	-	665,034	-	-	-	-	-	-	-	-	-	-
COGS																												
Standard COGS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	566,589	-	-	327,620	-	-	-	-	-	-	-	-	-	-
IC COGS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	129,226	-	-	-	-	-	-	-	-	-	-	-	-	-
OCCS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	112,558	-	-	(51,860)	-	-	-	-	-	-	-	-	-	-
Total COGS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	808,373	-	-	275,760	-	-	-	-	-	-	-	-	-	-
Operating Expenses																												
Salaries & Benefits	1,486,855	-	-	-	-	-	-	-	-	-	-	-	-	-	1,040,057	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	20,974,285	-	-	-	-	-	-	-	-	-	-	-	-	-	(1,335,179)	-	-	13,155	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	22,461,140	-	-	-	-	-	-	-	-	-	-	-	-	-	(295,122)	-	-	13,155	-	-	-	-	-	-	-	-	-	-
Non-Operating Expenses																												
Amortizations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Currency	(1,493,806)	-	-	-	-	-	-	-	-	-	-	(113,324)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Interest	2,541,427	-	-	-	-	-	-	-	-	-	24,832	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-recurring charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Income Expense	(171,628)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(12,587)	-	-	-	-	-	-	-	-	-	-
Disposal of Business	26,928,619	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restructuring	550,998	-	-	-	-	-	-	-	-	-	-	-	-	-	(58,955)	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non-Operating Expenses	28,355,610	-	-	-	-	-	-	-	-	-	(88,492)	-	-	-	(58,955)	-	-	(12,587)	-	-	-	-	-	-	-	-	-	-
Net Income	\$ (50,816,750)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 88,492	\$ -	\$ -	\$ -	\$ 1,136,535	\$ -	\$ -	\$ 388,707	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -

In re: Vyair Medical, Inc., et al.

Case No.: 24-11217 (BLS)
Reporting Period 10/1/2024 - 10/31/2024

Bank Reconciliations

The Debtors hereby submit this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations and journal entries.

The Debtors' standard practice is to ensure that bank reconciliations are completed before closing the books each reporting period. I attest that each of the Debtors' bank accounts has been reconciled in accordance with their standard practices.

/s/ Charles N. Braley
Signature of Authorized Individual

11/21/2024
Date

Charles N. Braley
Printed Name of Authorized Individual

Chief Restructuring Officer
Title of Authorized Individual